Improving visual ability in patients with retinal prosthesis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates innovative methods of retinal stimulation and training aimed at enhancing the visual capabilities of participants with retinal prostheses. It focuses on testing new visual processing units (VPUs) that utilize asymmetric waveforms and bipolar stimulation to improve shape perception. Participants will undergo auditory-visual training to facilitate better integration of visual information from the prosthesis. The goal is to optimize the functionality of the retinal prosthesis and improve overall visual perception.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Must be implanted with an Argus II Retinal Prosthesis system.
* Have 5 or more electrodes that create a perception with stimulation.
* Must be willing and able to comply with the protocol testing requirements.

Exclusion Criteria:

* Subjects participating in another investigatory drug or device study
* Any disease or condition that prevents understanding or communication of informed consent, study demands, and testing protocols.

Where it's running

• University of Michigan
  Ann Arbor, Michigan, United States Recruiting

Study contacts

• Principal investigator: James Weiland — University of Michigan
• Study coordinator: James Weiland
• Email: weiland@umich.edu
• Phone: 661-713-4603

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Functional visual field and navigation testing for moderate-to-profound inherited retinal disease

  This project will test whether functional visual field and navigation tests can measure real-world vision and mobility in people with moderate-to-profound inherited retinal diseases.

  Recruiting Ray Therapeutics, Inc. · Irvine, California · NCT07502664

• OCT-980 oral treatment for rhodopsin-associated autosomal dominant retinitis pigmentosa

  This program will test whether the oral drug OCT-980 is safe, well tolerated, and shows signs of benefit in adults with RHO-associated autosomal dominant retinitis pigmentosa and in healthy volunteers.

  Recruiting at 2 sites Phase 1/2 Octant, Inc. · Portland, Oregon and 1 other locations · NCT07408232

• Course of EYS-associated retinitis pigmentosa in adults from Russia and former CIS

  We will follow adults with pathogenic EYS gene variants from Russia and former CIS for four years to try to find reliable vision and retinal measures for future treatments.

  Recruiting Sensor Technology for Deafblind · Moscow · NCT07228793

• ZVS203e eye gene-editing therapy for a specific RHO-related retinitis pigmentosa

  This trial tests a single subretinal injection of ZVS203e to see if it’s safe and can help a specific RP caused by an RHO mutation.

  Recruiting Phase 1/2 Chigenovo Co., Ltd · Beijing, Beijing Municipality · NCT06952842

• Testing IGT001 for treating Retinitis Pigmentosa

  This study is testing a new treatment called IGT001 for people with retinitis pigmentosa to see if it can help improve their vision and how safe it is to use.

  Recruiting Phase 1 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT06936787

• Safety of a one-time DSP-3077 retinal sheet injection in adults with retinitis pigmentosa

  This will test whether a single subretinal injection of DSP-3077 retinal sheets is safe and well tolerated in adults with retinitis pigmentosa.

  Recruiting at 2 sites Phase 1/2 Sumitomo Pharma America, Inc. · Boston, Massachusetts and 1 other locations · NCT06891885

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.